Public request
Public Legal & Compliance Pack
Singapore and India compliance statements, regulatory boundaries, ISO/BIS roadmap, and public disclaimers.
Singapore & India Legal Profile
Last updated: 27 June 2026
Provenant maintains separate public compliance position statements for priority operating jurisdictions. Additional countries can be added as expansion planning progresses.
Republic of Singapore Compliance
Public regulatory and compliance statement for Republic of Singapore privacy, digital health, medical-device, AI governance, ISO-aligned readiness, investor, and pilot-readiness considerations.
Republic of India Compliance
Public regulatory and compliance statement for Republic of India DPDP, CDSCO/medical-device, telemedicine, healthcare advertising, ISO/BIS readiness, securities, and institutional pilot considerations.
Provenant AI Labs designs its commercial website and enterprise engagement practices with reference to Singapore's PDPA baseline for personal data protection. For customer deployments, data handling responsibilities, roles, security measures, retention, access controls, and breach procedures should be documented in the applicable contract, statement of work, or data protection addendum.
Provenant AI products are positioned as localized operational infrastructure. Deployments should be assessed for purpose limitation, data minimization, security, human oversight, validation, review logging, and suitability for the customer's regulated environment. Healthcare or industrial use cases may require additional customer-side regulatory, clinical, safety, cybersecurity, or procurement approvals.
Public product pages describe pilot concepts and stakeholder evaluation configurations powered by the PeachBot platform. They do not represent Health Sciences Authority (HSA) approval, medical-device registration, clinical validation, or authorization for diagnosis, treatment, monitoring, or patient management. Any Singapore deployment must be reviewed against the intended use, applicable HSA medical-device requirements, institutional governance, PDPA obligations, cybersecurity expectations, and site procurement processes before use in clinical or operational settings.
Public product and case-study pages are not advertisements for diagnosis, cure, mitigation, treatment, monitoring, or prevention of disease in India. They are intended for qualified institutional workflow discussion only. Provenant products are not represented as CDSCO-registered or approved medical devices, diagnostic systems, treatment systems, monitoring systems, or patient management systems in India. Any India deployment must undergo classification, licensing, registration, clinical, cybersecurity, procurement, and institutional review under applicable Indian law, including the Medical Devices Rules, 2017 where relevant.
Provenant AI Labs does not provide medical consultation or telemedicine services to patients. Any India telemedicine service must be provided by appropriately qualified Registered Medical Practitioners and healthcare institutions under applicable National Medical Commission, Ministry of Health and Family Welfare, state medical council, and institutional requirements.
Do not test, scan, or probe Provenant AI Labs systems without written authorization. Security concerns should be responsibly reported to the company through an approved contact channel once the production disclosure process is published.
Document Library
Public-facing documents become available immediately after a successful enquiry submission through a short-lived download link.
Public request
Singapore and India compliance statements, regulatory boundaries, ISO/BIS roadmap, and public disclaimers.
Public request
PDPA and DPDP-facing privacy summary for enquiries, retention, rights handling, and contact routing.
Public request
ISO/IEC, ISO medical-device, telehealth, laboratory, and India BIS/ISI readiness roadmap.